BioSpace News Archive

Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that it is hosting a key opinion leader (KOL) call on a novel mechanism for the treatment of glaucoma on Friday, June 12, 2020 at 11:30am Eastern Time. The call will feature presentations by Dr. Paul Kaufman M.D. (University of Wisconsin) and

TruLife Distribution continues their streak of successful attendance at ECRM’s unprecedented all-virtual conference. With strong connections to many of the leading retail markets in the United States,

Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced the initiation of a clinical trial aimed at demonstrating safety and efficacy of its immune-boosting

NOCD, a telehealth company that specializes in identifying and treating people with obsessive-compulsive disorder (OCD), announced today the publication in the journal, Behavior Therapy, of a study from Columbia University Medical Center and the New York State Psychiatric Institute on the use of the Company’s mobile app.

Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira® Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (

Sherlock Biosciences and Integrated DNA Technologies (IDT) today announced the companies have entered into a strategic collaboration to enable large-scale manufacturing of the Sherlock™ CR

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US Patent

Titan Medical Inc. (“ Titan ” or the “ Company ”) ( TSX:TMD ) ( Nasdaq:TMDI ), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“ MIS ”), is pleased to announce today that it has entered into definitive agreements with a single healthcare-foc

Company presentation will highlight progress towards transitioning to a fully integrated commercial stage company with an initial focus on vaginal yeast infection

In the initial scramble to quell the impact of the COVID-19 pandemic, the rapid antibody test market was been flooded. Not all tests are created equal and the COVID-19 crisis introduced the opportunity to try unproven players in rapid diagnostic testing.